|Last Update: 06/18/13 - 4:00 PM EDT|
|YTD Performance: -21.18%|
|Previous Close: $18.60|
|52 Week Range: $16.37 - $30.59|
|Oustanding Shares: 54,540,255|
|Market Cap: 1,014,994,146|
|Qtr (06/13)||Qtr (09/13)||FY (12/13)||FY (12/14)|
|Number of Analysts||7||7||8||7|
|Growth Rate (Year over Year)||-107.14%||-160.71%||-67.50%||468.50%|
VOLC was downgraded to Market Perform, William Blair said. Company has poor earnings visibility.
VOLC was downgraded from Buy to Neutral, Goldman Sachs said. Company was also cut from the Conviction List. Base business will likely continue to face pressure. $25 price target.
VOLC was downgraded from Outperform to Neutral, Credit Suisse said. $32 price target. Estimates also cut, as the company sold new debt and may make new acquisitions.
VOLC was downgraded to Market Underperform from Market Perform, JMP Securities said. $20 price target. Longer term fundamentals of PCI market unlikely to reverse themselves.
VOLC was initiated with an Outperform rating, Credit Suisse said. $36 price target. Company has a solid growth profile and is a potential takeover target.
VOLC was placed on the Conviction Buy list, according to Goldman Sachs. Estimates also boosted, given solid penetration of FM technology. $36 price target.
Shares of VOLC upgraded to Buy from Hold, Jefferies said. $37 price target. Rare story in medical devices that checks all the boxes.
VOLC was upgraded from Neutral to Buy, Goldman Sachs said. $36 price target. FFR business should drive growth over the coming quarters.
VOLC estimates were boosted through 2015, Goldman Sachs said. Company is gaining market share. Neutral rating and new $28 price target.